AgingResearch.NewsJoin free

Empagliflozin + topiramate

Empagliflozin + topiramate has been studied in 1 paper since 2024: 1 trial in people. The newest paper, Oct 3, 2024: “Randomized study of the effects of empagliflozin and topiramate dual therapy on anthropometric and metabolic indices in non-diabetic individuals with overweight/obesity on a calorie-restricted diet”.

Intervention

1 paper studies it6 findingsUpdated

PubChemPubChemChEBIChEBI

See all 1 papers on empagliflozin + topiramate

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“The EMPA/TPM group had a greater percent change of weight at weeks 8 (-4.84 ± 1.02 vs. − 3.50 ± 0.96) and 12 (− 8.92 ± 1.80 vs. − 4.93 ± 1.17).”
Randomized study of the effects of empagliflozin and topiramate dual therapy on anthropometric and metabolic indices in non-diabetic individuals with overweight/obesity on a calorie-restricted dietEating and weight disorders : EWD2024doi:10.1007/s40519-024-01692-2

1 of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Against: findings that point the other way from most findings on the same outcome.

  • 1 lab in 1 country
  • 1 finding against
  • Funder: Shahid Beheshti University of Medical Sciences
  • Human trial1

Studies in people

1 study gave empagliflozin + topiramate to people and measured what changed.

What changedDesignPeopleSource

down: Decreases body weight−8.92 ± 1.80 vs. −4.93 ± 1.17%

down: Decreases body fat mass

no change: Has no effect on fat-free mass percentage

Randomized trial12-week44 people16 males and 28 femalesaged over 18 yearsIndividuals without diabetes and with overweight/obesityEating and weight disorders : EWD, Oct 3, 2024

What did studies of empagliflozin + topiramate find?

5

Studies of empagliflozin + topiramate measured 5 outcomes; the most studied are body weight (1 study), metabolic and inflammatory markers (1) and blood pressure (1).

Body weight

downin humans1

1 study

  1. Empagliflozin + topiramate decreases body weight in humans with calorie-restricted diet, versus placebo (percent change -8.92 ± 1.80 vs -4.93 ± 1.17 at week 12).

    “The EMPA/TPM group, compared to placebo, had a greater percent change of weight at week 12 (- 8.92 ± 1.80 vs. - 4.93 ± 1.17).”

    Human trialwith calorie-restricted diet, versus placeboempagliflozin 10 mg daily; topiramate 25 mg once daily then twice daily12 weeksn = 44

    Randomized study of the effects of empagliflozin and topiramate dual therapy on anthropometric and metabolic indices in non-diabetic individuals with overweight/obesity on a calorie-restricted diet

    Eating and weight disorders : EWD

  2. Empagliflozin + topiramate decreases body weight in humans (on a hypocaloric diet) (−8.92 ± 1.80 vs. −4.93 ± 1.17%).

    “The EMPA/TPM group had a greater percent change of weight at weeks 8 (-4.84 ± 1.02 vs. − 3.50 ± 0.96) and 12 (− 8.92 ± 1.80 vs. − 4.93 ± 1.17).”

    Human trialon a hypocaloric diet12-weekn = 44

    Randomized study of the effects of empagliflozin and topiramate dual therapy on anthropometric and metabolic indices in non-diabetic individuals with overweight/obesity on a calorie-restricted diet

    Eating and weight disorders : EWD

Metabolic and inflammatory markers

no changein humans1

1 study

  1. Empagliflozin + topiramate showed no clear effect on metabolic and inflammatory markers in humans (at week 12, versus placebo, with calorie-restricted diet) (P > 0.05).

    “At week 12, no statistically significant difference was observed between the two groups in any of mentioned variables (P > 0.05).”

    Human trialat week 12, versus placebo, with calorie-restricted dietempagliflozin 10 mg daily; topiramate 25 mg once daily then twice daily12 weeksn = 44

    Randomized study of the effects of empagliflozin and topiramate dual therapy on anthropometric and metabolic indices in non-diabetic individuals with overweight/obesity on a calorie-restricted diet

    Eating and weight disorders : EWD

More on Metabolic and inflammatory markers

Blood pressure

no changein humans1

1 study

  1. Empagliflozin + topiramate showed no clear effect on blood pressure in humans (on a hypocaloric diet).

    “However, no significant changes were observed in WC, glycemic and lipid profiles, blood pressure, or inflammation between the two groups.”

    Human trialon a hypocaloric diet12-weekn = 44

    Randomized study of the effects of empagliflozin and topiramate dual therapy on anthropometric and metabolic indices in non-diabetic individuals with overweight/obesity on a calorie-restricted diet

    Eating and weight disorders : EWD

Fat-free mass percentage

no changein humans1

1 study

  1. Empagliflozin + topiramate showed no clear effect on fat-free mass percentage in humans (on a hypocaloric diet).

    “However, there was no difference in the percent of change in fat-free percent between the two groups at week 12 (P = 0.577; Fig. D).”

    Human trialon a hypocaloric diet12-weekn = 44

    Randomized study of the effects of empagliflozin and topiramate dual therapy on anthropometric and metabolic indices in non-diabetic individuals with overweight/obesity on a calorie-restricted diet

    Eating and weight disorders : EWD

Body fat mass

downin humans1

1 study

  1. Empagliflozin + topiramate decreases body fat mass in humans (on a hypocaloric diet).

    “As shown in Fig., the EMPA/TPM group had a greater percent change of fat mass (A) and fat percent (B) at weeks 8 and 12 (P < 0.05).”

    Human trialon a hypocaloric diet12-weekn = 44

    Randomized study of the effects of empagliflozin and topiramate dual therapy on anthropometric and metabolic indices in non-diabetic individuals with overweight/obesity on a calorie-restricted diet

    Eating and weight disorders : EWD

Latest

Related